- $1.39bn
- $1.48bn
- $53.04m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 13 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -14.37% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 131.19 | ||
| Price to Tang. Book | 131.19 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 26.18 | ||
| EV to EBITDA | 45.81 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.48% | ||
| Return on Equity | n/a | ||
| Operating Margin | 60.93% | ||
Financial Summary
| Year End 30th Jun | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 10.29 | 17.16 | 91.28 | 234.6 | 53.04 | 206.09 | 300.69 | -3.44% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | -39.19 | +59.43 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
Directors
- Hollings Renton IND (79)
- Oleg Nodelman IND (49)
- Daniel Faga PRE (46)
- John Orwin NEC (61)
- Susannah Gray DRC (65)
- Christopher Murphy CFO (42)
- Owen Hughes DRC
- Last Annual
- June 30th, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- November 16th, 2005
- Public Since
- January 26th, 2017
- No. of Employees
- 104
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 29,895,244
- Address
- 10770 Wateridge Circle, Suite 210, SAN DIEGO, 92121
- Web
- https://www.anaptysbio.com/
- Phone
- +1 3026587581
- Auditors
- KPMG LLP
Latest News for ANAB
Upcoming Events for ANAB
Q4 2026 AnaptysBio Inc Earnings Release
Similar to ANAB
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 18:16 UTC, shares in AnaptysBio are trading at $46.45. This share price information is delayed by 15 minutes.
Shares in AnaptysBio last closed at $46.45 and the price had moved by +82.42% over the past 365 days. In terms of relative price strength the AnaptysBio share price has outperformed the S&P500 Index by +66.4% over the past year.
The overall consensus recommendation for AnaptysBio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAnaptysBio does not currently pay a dividend.
AnaptysBio does not currently pay a dividend.
AnaptysBio does not currently pay a dividend.
To buy shares in AnaptysBio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $46.45, shares in AnaptysBio had a market capitalisation of $1.39bn.
Here are the trading details for AnaptysBio:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ANAB
Based on an overall assessment of its quality, value and momentum AnaptysBio is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in AnaptysBio is $91.14. That is 96.21% above the last closing price of $46.45.
Analysts covering AnaptysBio currently have a consensus Earnings Per Share (EPS) forecast of $2.95 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AnaptysBio. Over the past six months, its share price has underperformed the S&P500 Index by -32.67%.
As of the last closing price of $46.45, shares in AnaptysBio were trading -8.56% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The AnaptysBio PE ratio based on its reported earnings over the past 12 months is 13. The shares last closed at $46.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
AnaptysBio's management team is headed by:
- Hollings Renton - IND
- Oleg Nodelman - IND
- Daniel Faga - PRE
- John Orwin - NEC
- Susannah Gray - DRC
- Christopher Murphy - CFO
- Owen Hughes - DRC